2022 ON-DEMAND: QM Series 11 Bundle - Overview of Corrective Action Plans

2022 ON-DEMAND: QM Series 11 Bundle - Overview of Corrective Action Plans

This module of the QM Series consists of sessions related to corrective action plans associated with cellular therapy programs and cord blood banks. Corrective Action Plans: Overview of Corrective Action Plans (February 16, 2022); QM Series 11, Corrective Action Plans: Developing a Corrective Action Plan (May 11, 2022); QM Series 11, Corrective Action Plans: Implement and Assess Effectiveness of Corrective Action Plan (August 24, 2022); QM Series 11, Corrective Action Plans, A Program's Perspective: (November 9, 2022)

Carlos Bachier, MD

Medical Director

Sarah Cannon Transplant and Cellular Therapy Program

Carlos R. Bachier, MD, is a board-certified Hematologist/Oncologist with the Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital in San Antonio, Texas. He is also the Medical Director of Research and Cellular Therapy. While growing up, Dr. Bachier spent summers working at the clinic of his uncle, a pediatric endocrinologist. It was there he became interested in the field of medicine, as it combined his love of science with "detective work," or finding out what is wrong with someone.

After completing a Bachelor of Science in Chemistry from Tulane University in New Orleans, LA, Dr. Bachier received his medical degree at the University of Puerto Rico School of Medicine in San Juan, Puerto Rico. While in Puerto Rico, one of his mentors showed him how fascinating oncology treatment was. Dr. Bachier found oncology interesting because of the science of it, and it was the beginning of DNA abnormalities being discovered that would help determine future therapies.

After completing both his Residency in Internal Medicine and Fellowship in Hematology in San Juan, he came to the University of Texas Health Science Center in San Antonio for a Fellowship in Hematology and Medical Oncology. He worked at the MD Anderson Cancer Center after completing his fellowship. In the late 1990s, he returned to San Antonio and worked at the Texas Transplant Institute, where he eventually became program director. Dr. Bachier was then recruited to the Sarah Cannon Center for Blood Cancer as program director and as Director of Cellular Therapy Research at Sarah Cannon Research Institute. After six years as the Program Director at the Sarah Cannon Center for Blood Cancer in Nashville, Tennessee, he returned to Methodist Hospital in San Antonio.

He is a member of numerous professional associations, including the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation. He is also a member of the Sarah Cannon Blood Cancer Network, leading its Cellular Therapy Working Group.

Bachier: Sanofi: Speakers Bureau; AlloVir: Honoraria; CRISPR: Honoraria; Juno Therapeutics, a Bristol-Myers Squibb Company: Honoraria.

Lisa Cantwell, MHA, CPHQ

Quality Manager

Stem Cell Transplant and Cellular Therapy Program of the Holden Comprehensive Cancer center at the University of Iowa

Lisa Cantwell is a certified Professional in Healthcare Quality (CPHQ). Twenty years of healthcare service management experience, including employee supervision, financial management, project management, budgeting, marketing, policy development, program development, quality assurance, and regulatory compliance. Lisa is the Senior Director of Authorized Treatment Center Operations at Iovance Biotherapeutics, Inc.

Cantwell:  employee at Iovance Biotherapeutics, Inc.

  • Registration Closed

Key:

Complete
Failed
Available
Locked
2022 QM Series 11 Webinar: Overview of Corrective Action Plans
Recorded: February 16, 2022 You must register to access.